|
Name |
Smardaesidin A, (rel)-
|
Molecular Formula | C20H28O6 | |
IUPAC Name* |
(1S,2R,4S,9R,10S,13R,14S,15S)-2,10-dihydroxy-14-(hydroxymethyl)-5,5,13-trimethyl-16-oxapentacyclo[7.6.2.01,10.04,9.013,15]heptadecane-3,17-dione
|
|
SMILES |
C[C@]12CC[C@@]3([C@@]45CCCC([C@@H]4C(=O)[C@@H]([C@]3([C@H]1[C@@H]2CO)OC5=O)O)(C)C)O
|
|
InChI |
InChI=1S/C20H28O6/c1-16(2)5-4-6-18-13(16)11(22)14(23)20(26-15(18)24)12-10(9-21)17(12,3)7-8-19(18,20)25/h10,12-14,21,23,25H,4-9H2,1-3H3/t10-,12-,13-,14-,17+,18-,19-,20-/m0/s1
|
|
InChIKey |
GKARPIJLSMMCSR-ZSPSABHSSA-N
|
|
Synonyms |
Smardaesidin A; Smardaesidin A, (rel)-; CHEBI:69487; Q27137825
|
|
CAS | NA | |
PubChem CID | 56599461 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 364.4 | ALogp: | 0.8 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 26 | QED Weighted: | 0.605 |
Caco-2 Permeability: | -5.242 | MDCK Permeability: | 0.00003750 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.511 |
Human Intestinal Absorption (HIA): | 0.031 | 20% Bioavailability (F20%): | 0.108 |
30% Bioavailability (F30%): | 0.087 |
Blood-Brain-Barrier Penetration (BBB): | 0.866 | Plasma Protein Binding (PPB): | 54.61% |
Volume Distribution (VD): | 0.557 | Fu: | 57.20% |
CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.585 |
CYP2C19-inhibitor: | 0.018 | CYP2C19-substrate: | 0.774 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.07 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.116 |
CYP3A4-inhibitor: | 0.247 | CYP3A4-substrate: | 0.225 |
Clearance (CL): | 5.068 | Half-life (T1/2): | 0.421 |
hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.091 |
Drug-inuced Liver Injury (DILI): | 0.167 | AMES Toxicity: | 0.049 |
Rat Oral Acute Toxicity: | 0.851 | Maximum Recommended Daily Dose: | 0.202 |
Skin Sensitization: | 0.049 | Carcinogencity: | 0.876 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.038 |
Respiratory Toxicity: | 0.772 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002731 | 0.412 | D0KR5B | 0.270 | ||||
ENC001409 | 0.404 | D0R7JT | 0.265 | ||||
ENC002832 | 0.384 | D0L2LS | 0.262 | ||||
ENC002056 | 0.369 | D0U3GL | 0.260 | ||||
ENC002917 | 0.337 | D0Q6NZ | 0.259 | ||||
ENC002007 | 0.330 | D0D1SG | 0.259 | ||||
ENC002918 | 0.326 | D04VIS | 0.255 | ||||
ENC001193 | 0.325 | D08PIQ | 0.254 | ||||
ENC001452 | 0.322 | D0Y2YP | 0.252 | ||||
ENC005585 | 0.318 | D0CW1P | 0.250 |